U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. Reports, Manuals, & Forms
  4. Reports
  5. Economic Impact Analyses of FDA Regulations
  6. Summary: Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use (Final Rule)
  1. Economic Impact Analyses of FDA Regulations

Summary: Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use (Final Rule)

The Food and Drug Administration (FDA) is amending the regulations applicable to blood and blood components, including Source Plasma, to make the donor eligibility and testing requirements more consistent with current practices in the blood industry, to more closely align the regulations with current FDA recommendations, and to provide flexibility to accommodate advancing technology. In order to better assure the safety of the nation’s blood supply and to help protect donor health, FDA is revising the requirements for blood establishments to test donors for infectious disease, and to determine that donors are eligible to donate and that donations are suitable for transfusion or further manufacture. FDA is also requiring establishments to evaluate donors for factors that may adversely affect the safety, purity, and potency of blood and blood components or the health of a donor during the donation process. Accordingly, these regulations establish requirements for donor education, donor history, and donor testing. These regulations also implement a flexible framework to help both FDA and industry to more effectively respond to new or emerging infectious agents that may affect blood product safety.

Regulatory Impact Analysis

Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use (Final Rule) (PDF-86 KB)

Federal Register: 80 FR 29841, May 22, 2015

Docket: FDA-2006-N-0040 (formerly Docket No. 2006-N-0221)

Back to Top